Literature DB >> 2325422

Intraarterial infusion chemotherapy in regionally advanced malignant melanoma.

A Calabro1, S E Singletary, C H Carrasco, S S Legha.   

Abstract

The therapeutic effectiveness of intraarterial cisplatin (CDDP) and dacarbazine (DTIC) infusion was examined in 30 evaluable patients with regionally advanced melanoma that was refractory to standard treatments. Objective responses were achieved in 11 patients (37%), including three complete (10%) and eight partial (27%) tumor regressions. Successful debulking surgery was performed in seven of the eleven patients with response. Six remained free of regional disease after a median time of 25 months, and four are also free of distant metastases at 24+, 25+, 41+, and 54+ months. Nineteen of thirty patients with no significant tumor response underwent alternative treatments. Debulking surgery was performed in nine, but with little palliative gain, since seven relapsed at a median time of 5 months. Our results suggest that a combined therapeutic approach--preoperative chemotherapy followed by surgery in responding tumors--represents an effective treatment for patients with regionally advanced melanoma.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2325422     DOI: 10.1002/jso.2930430410

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  2 in total

1.  Molecular clonality of in-transit melanoma metastasis.

Authors:  T Nakayama; B Taback; R Turner; D L Morton; D S Hoon
Journal:  Am J Pathol       Date:  2001-04       Impact factor: 4.307

2.  Case Report: Response to Intra-arterial Cisplatin and Concurrent Radiotherapy Followed by Salvage Surgery in a Patient With Advanced Primary Sinonasal Low-Grade Non-intestinal Adenocarcinoma.

Authors:  Hirohiko Tachino; Hiromasa Takakura; Hideo Shojaku; Michiro Fujisaka; Katsuichi Akaogi; Hideto Kawabe; Norihito Naruto; Hiroko Shojaku; Kyo Noguchi; Shigeharu Miwa; Johji Imura; Yoshinobu Maeda
Journal:  Front Surg       Date:  2020-12-10
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.